As RASSF1A methylation occurs at the early stage of numerous human cancers and its inactivation is associated with more aggressive tumor phenotype [23, 34], increase of TNT-1 formation in the absence of RASSF1A, could act by stimulating metabolic adaptation of cancer cells at the early stage, and could further participate to the emergence of resistance during drug treatment. The gene discussed is RASSF1; the disease is cancer.